The US Food and Drug Administration (FDA) recently issued emergency use authorizations (EUA) to make both bamlanivimab and casirivimab/imdevimab combination (Regeneron) monoclonal antibodies (MAb) available for clinical use (http://www.covid19treatmentguidelines.nih.gov/whats-new/). These MAbs are approved for the treatment of non-hospitalized patients with mild to moderate COVID-19 (with positive results of direct viral tests for SARS-CoV-2) who are at high risk for progressing to severe disease and/or hospitalization. Skilled Nursing Facilities (SNF) have been identified as settings where MAb treatment may be beneficial.
|Inclusion Criteria||Exclusion Criteria|
Candidates are required to fit one of the following criteria:
Candidates must also fit anyone of the following high-risk conditions:
Some patients are excluded from using the MAb product. The drugs may not be given if the patient meets any of the following criteria:
As pharmacies need to prepare the infusions in advance, LAC DPH has been consulting with SNF pharmacists on the best ordering and procurement processes to keep a supply stocked for SNFs when their residents meet the clinical criteria for MAb.